Helix BioPharma Corp.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a HBPCF research report →
About the company
Helix BioPharma Corp. is a Canadian enterprise focused on immuno-oncology. The company's research and development efforts include L-DOS47, a drug candidate aimed at treating non-small cell lung cancer, and V-DOS47, which is designed to interact with vascular epithelial growth factor receptor 2 (VEGFR2).
- CEO
- Thomas Mehrling
- IPO
- 2009
- Employees
- 7
- HQ
- Toronto, ON, CA
Price Chart
- Market Cap
- $130.61M
- P/E
- -31.82
- P/S
- 0.00
- P/B
- 7.28
- EV/EBITDA
- -33.87
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -21.54%
- ROIC
- -21.65%
- Revenue
- $0 · 0.00%
- Net Income
- $-5,000,000 · -53872.37%
- EPS
- $-0.07 · -67300.00%
- Op Income
- $-5,000,000
- FCF YoY
- 23.56%
- 52W High
- $1.73
- 52W Low
- $0.60
- 50D MA
- $1.72
- 200D MA
- $1.58
- Beta
- -0.38
- Avg Volume
- 16
Get TickerSpark's AI analysis on HBPCF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our HBPCF coverage
Recent articles, reports, and earnings notes.
No research on HBPCF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate HBPCF report →Similar companies
Peers in the same neighborhood.